Skip to main content

Year: 2025

Azerion completes refinancing of outstanding senior secured bonds

THIS DOCUMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE MARKET ABUSE REGULATION (EU) 596/2014. Press release Amsterdam, 13 October 2025 at 07:00 CEST Azerion Group N.V. completes refinancing of outstanding senior secured floating rate bonds maturing in October 2026 Azerion Group N.V. is pleased to confirm the completion of the refinancing of its outstanding senior secured bonds maturing in October 2026 with ISIN NO0013017657 (the “Existing Bonds“), with the successful early redemption of all outstanding Existing Bonds. For further information, please contact: Contact: Andrew Buckman – Chief Growth Officer ir@azerion.com Media press@azerion.com About Azerion Founded in 2014, Azerion (EURONEXT: AZRN) is one of Europe’s largest...

Continue reading

Corbion reports the progress of its share buyback program 6 October – 10 October 2025

Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 6 October up to and including 10 October 2025 a total of 35.578 shares were repurchased at an average price of €16.7661 for a total amount of €596,504.09 To date, the total consideration for shares repurchased amounts to €4,525,155.64 representing 45.25% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of the share buyback program on its website: https://www.corbion.com/Investor-relations/shareholder-information This overview contains detailed information on the daily amount of repurchased shares and individual share purchase transactions.Attachment2025 SBB weekly update 20251010

Continue reading

Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types

Basel, 13 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held 17-21 October 2025 in Berlin, Germany. The data underscore Roche’s commitment to deliver transformative medicines for some of the most challenging cancer types, including breast cancers, lung cancers, gastrointestinal and genitourinary cancers. Key presentations include:Giredestrant: Primary results from the phase III evERA Breast Cancer study, the first positive head-to-head phase III trial investigating a selective oestrogen receptor (ER) degrader-containing regimen versus a standard of care combination in the post-cyclin-dependent kinase inhibitor setting for people with ER-positive, human epidermal growth...

Continue reading

VGP Acquires Site of Former Paper Mill in Hagen, Near Dortmund, to Develop Business Park

The company acquires the approximately 280,000 m² site of the former Kabel Premium Pulp & Paper GmbH First plot acquisition of VGP in North Rhine-Westphalia, 20 minutes from the centre of Dortmund VGP plans to develop a modern business and industrial park13 October 2025, 7:00am, Antwerp, Belgium /Düsseldorf, Germany: VGP, a pan-European developer, manager and owner of high-quality logistics and semi-industrial real estate as well as a provider of renewable energy solutions, has acquired the former factory site of Kabel Premium Pulp & Paper GmbH in Hagen. The property covers around 280,000 square metres and was sold to VGP on 9 October 2025 by the insolvency administrator as part of the insolvency proceedings opened in June 2025. The traditional paper mill had been based at the Hagen site for almost 130 years. The city of Hagen,...

Continue reading

Share repurchase programme: Transactions of week 41 2025

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 2,141,532 609.38 1,305,001,0636 October 2025 4,500 710.20 3,195,8917 October...

Continue reading

Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook Männedorf, Switzerland, October 13, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today provided a qualitative update on its performance for the third quarter of 2025.Sales for the third quarter increased by a mid-single-digit percentage in local currencies, representing a further sequential improvement after a mid-single-digit decline in Q1 and a low-single-digit decline in Q2. At the segment level, the Life Sciences Business recorded a low-single-digit sales decline and the Partnering Business achieved a sales increase in the low teens percentage range, both in local currencies and in line with expectations....

Continue reading

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announces results from the FRUSICA-2 registration clinical trial of the fruquintinib and sintilimab combination for the treatment of patients with locally advanced or metastatic renal cell carcinoma. Results of the Phase III part of the study will be presented on Friday, October 17, 2025 during the European Society for Medical Oncology (“ESMO”) Congress in Berlin, Germany. FRUSICA-2 is a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of fruquintinib in combination with...

Continue reading

Okeanis Eco Tankers Corp. – Director Resignations

ATHENS, Greece, Oct. 13, 2025 (GLOBE NEWSWIRE) — Okeanis Eco Tankers Corp. (“OET” or the “Company”) (NYSE:ECO / OSE:OET) today announced that each of Robert Knapp and Joshua Nemser have decided to resign as directors of the Company, effective October 10, 2025. The two resignations did not result from any disagreement with the Company or its management. The board of directors of the Company has not yet determined whether to reduce the size of the board or to fill the relevant vacancies. The board of directors remains comprised of a majority of independent directors. The composition of each of the committees of the board of directors remains the same and is unaffected by these resignations, except for the remuneration committee, which remains comprised of Charlotte Stratos and Francis “Frank” Dunne. Ioannis Alafouzos, Chairman of...

Continue reading

Market Alert: AlphaTON Capital Continues in Growth Mode and Purchases an additional 300,000 TON

Dover, DE, Oct. 12, 2025 (GLOBE NEWSWIRE) — AlphaTON Capital Corp. (Nasdaq: ATON) stated that during the market conditions of the past week, AlphaTON Capital is still expanding its TON Treasury, purchasing an additional 300,000 TON off the open market today, adding to the 1.1million TON purchased off the open market last week. With zero liquidations and the majority of its TON assets unencumbered, AlphaTON Capital maintains a debt-to-equity ratio of 0.07. “AlphaTON Capital is continuing to grow its market share in TON while maintaining prudent asset management policies in volatile market conditions.” Enzo Villani, Chief Investment Officer, stated, “Volatility in the markets has been a reality across all trading exchanges since the beginning of market systems. Our team is focused on managing risk and maintaining proper leverage...

Continue reading

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: Recent Developments Include FX Signing a Deposit Agreement for 1,000 FX Super One MPV’s with ZEVO, a Pioneer of Peer-to-Peer EV Sharing Platform in the U.S.

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: Recent Developments Include FX Signing a Deposit Agreement for 1,000 FX Super One MPV’s with ZEVO, a Pioneer of Peer-to-Peer EV Sharing Platform in the U.S.Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: Recent Developments Include FX Signing a Deposit Agreement for 1,000 FX Super One MPV’s with ZEVO, a Pioneer of Peer-to-Peer EV Sharing Platform in the U.S.ZEVO deposit agreement represents another innovative breakthrough in the Company’s B2B2C sales model, following the car rental, FX Par, real estate brokerage, and MCN agencies. FF Announced Pinnacle Real Estate Group President Calvin Gong as the latest FF 91 2.0 Futurist Alliance Co-Creation Officer at a ceremony in Los Angeles on Oct. 8.LOS ANGELES, Oct. 12, 2025 (GLOBE NEWSWIRE)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.